BioLineRx (BLRX) Common Equity (2010 - 2026)

BioLineRx's Common Equity history runs 16 years deep, the most recent figure standing at $23.3 million for Q4 2025.

• In Q4 2025, Common Equity rose 73.43% year-over-year to $23.3 million; the TTM figure through Dec 2025 stood at $23.3 million (up 73.43% YoY), while the FY2025 annual figure was $23.3 million, up 73.43% from the prior year.
• Common Equity for Q4 2025 stood at $23.3 million, up from $19.5 million in the prior quarter.
• The five-year high for Common Equity was $73.9 million in Q2 2021, with the low at $8.5 million in Q3 2024.
• The 5-year median for Common Equity is $22.2 million (2023), against an average of $36.2 million.
• The sharpest annual moves came in 2021 and 2023: Common Equity surged 209.06% in 2021, then tumbled 76.35% in 2023.
• BioLineRx's Common Equity stood at $68.1 million in 2021, then fell by 25.33% to $50.8 million in 2022, then slumped by 73.99% to $13.2 million in 2023, then rose by 1.8% to $13.5 million in 2024, then soared by 73.43% to $23.3 million in 2025.
• Business Quant data shows BLRX's Common Equity at $23.3 million in Q4 2025, $19.5 million in Q3 2025, and $20.1 million in Q2 2025.